To print: Select File and then Print from your browser's menu

Title: Tazarotene Gel For Acne Vulgaris Proves Safe And Effective

URL: http://archderm.ama-assn.org/issues/v138n4/abs/dst10056.html

Archives of Dermatology 2002;138:481-489. "Successful Treatment of Acne Vulgaris Using a New Method : Results of a Randomized Vehicle-Controlled Trial of Short-Contact Therapy With 0.1% Tazarotene Gel"
04/22/2002 08:04:01 AM
By David Loshak

Newly developed short-contact 0.1% tazarotene gel is a safe and effective treatment for acne, minimising local adverse effects. To assess the gel's tolerability and effectiveness in treating facial acne, dermatologists at Mount Sinai School of Medicine, New York, United States, conducted a 12-week randomised, masked, vehicle-controlled trial of the tazarotene gel versus a non-medicated gel control. Three groups of 33 patients each were randomly assign to receive 0.1% tazarotene gel twice daily, 0.1% tazarotene gel once daily plus vehicle gel once daily, or vehicle gel twice daily. Patients adjusted applications to between 30 seconds and five minutes, as tolerated. By week 12, the two tazarotene regimens achieved significantly greater mean percentage reductions in non-inflammatory lesions (41-46 percent) than vehicle gel twice daily (2 percent). The two tazarotene regimens also achieved significantly greater mean percentage reductions in inflammatory lesions (34-38 percent) than vehicle gel twice daily (9 percent). In addition, the two tazarotene regimens were superior in terms of the percentage of treatment successes (61-64 percent versus 15 percent with the vehicle gel), and in their reduction of overall disease severity (29-30 percent versus three percent). Local adverse effects did not differ significantly between the three groups after the fourth week of the study.

http://archderm.ama-assn.org/issues/v138n4/abs/dst10056.html

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.